# The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

> **NCT00868283** · PHASE4 · COMPLETED · sponsor: **Ever Neuro Pharma GmbH** · enrollment: 1071 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Cerebrolysin
- **DRUG:** 0.9% Saline Solution

## Key facts

- **NCT ID:** NCT00868283
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2010-10
- **Final completion:** 2011-02
- **Target enrollment:** 1071 (ACTUAL)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868283, "The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00868283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*